Novartis Backs Remibrutinib at $4B+ MS Peak Sales as Barclays Cuts Forecast

2.8 · 1d ago · WORLD · FINANCE

The Facts

  • Novartis CEO Vas Narasimhan said remibrutinib, an experimental multiple sclerosis drug, could be one of the company's largest medicines in history, and the company backed peak annual MS sales of more than $4 billion. CNBC only
  • Barclays cut its peak sales forecast for remibrutinib after detailed results from two late-stage trials showed a smaller relapse reduction in MS patients than analysts expected. CNBC only
  • Novartis has guided for more than $8 billion in total remibrutinib sales across all indications, including indications other than relapsing MS. CNBC only
  • Novartis reported sales growth this week despite losing key patent protection for heart drug Entresto. CNBC only
  • Barclays analysts said Kisqali and Kesimpta face patent expirations around 2032, representing $18 billion in peak sales. CNBC only
Dive deeper · 6 more factsShow less
  • Novartis sees peak annual sales opportunities of more than $6 billion for Kesimpta and more than $4 billion for remibrutinib in relapsing MS. CNBC only
  • Penn MS specialist Amit Bar-Or said remibrutinib appears to have a promising safety profile but is unlikely to control relapsing MS as well as anti-CD20 antibodies such as Kesimpta; no head-to-head trials exist against fenebrutinib or anti-CD20 drugs. CNBC only
  • Morningstar analyst Jay Lee called the $4B+ forecast 'within the realm of possibility' but not 'de-risked'. CNBC only
  • The RESHAPE trial, in patients aged 40 to 70 taking Roche's Ocrevus, is expected to read out in 2028; a progressive MS trial is expected in 2031. CNBC only
  • Remibrutinib is already approved for certain forms of chronic hives; a late-stage hidradenitis suppurativa trial is expected to read out before Nov. 19. CNBC only
  • Novartis is due to outline its long-term growth strategy in mid-November. CNBC only

Context

Novartis is defending its sales outlook for remibrutinib, a BTK inhibitor for multiple sclerosis, after Barclays lowered its forecast following late-stage trial data. The company is also facing investor focus on patent expirations for Kisqali and Kesimpta around 2032, following the loss of Entresto protection.

An outside specialist and a Morningstar analyst said the drug's market position depends on comparisons with Roche's fenebrutinib, pricing, tolerability and future trial results. The article text was truncated.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 1.

3 Critical Reader The story centers on analyst forecast changes and company rhetoric defending a sales outlook for an experimental drug still years from readout, with no new concrete regulatory, financial, or market action beyond a Barclays estimate cut.
3 Global Affairs Analyst This is a pharma analyst forecast dispute: Barclays cut a peak sales estimate and Novartis's CEO defended its outlook, which are statements and analyst opinions rather than a concrete new corporate action with broad societal impact, though the trial data and patent cliff give it some market significance.
3 News Editor The story centers on analyst forecast changes and executive rhetoric about an experimental drug with no new regulatory or market action, which is commercially notable but limited in broad impact.
3 Business Analyst The story centers on analyst forecast revisions and company rhetoric defending a drug's sales outlook without a new concrete corporate or regulatory action, though the Barclays forecast cut for a large pharma pipeline asset gives it modest market relevance.
3 Science & Tech Analyst This is mainly analyst forecast revisions and executive statements about an experimental drug still awaiting key trial readouts, with no new approval, trial result, or market-moving corporate action reported.
2 Informed Citizen This is analyst forecast revisions and company rhetoric about an experimental drug's sales outlook, with no concrete regulatory approval, trial readout, or market-changing action in the near term, so it has limited impact on ordinary people.
2 Policy Expert The story centers on analyst forecast changes and company statements about sales expectations for an experimental drug, which are rhetoric and analysis rather than a concrete government or regulatory action with broad impact.

Source

← All stories